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Evaluation of microphthalmia associated transcription factor (MITF)
expression in peripheral blood of a population with malign melanoma
and control population and cell lines*
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SUMMARY
Background: The incidence of malign melanoma tumours has increased more rapidly than any other type of cancer; this
has intensified the searching for tools that facilitate early detection of melanoma. Microphthalmia associated transcription
factor (MITF) is currently known as being a master melanocyte regulator. The article analyses MITF gene expression in
peripheral blood of individuals suffering from melanoma, compared to people without any type of cancer and some cell lines.
Materials and methods: Thirty one samples of peripheral blood were used: 19 from patients having melanoma and 12 from
healthy people. Then RNA was extracted from these samples. MITF and housekeeping genes (β2M and GAPDH) expression
levels were then quantified by real-time PCR. Five cell lines were also used to determine the MITF expression.
Results: MITF gene expression could be observed in all individuals, though no statistical significant differences were found
among expression levels in the groups studied (p=0.09). Even so, MITF expression in the group of patients suffering from
melanoma was much more variable than that observed in the group of cancer-free people. Expression was detected in the cell
line AGS (gastric adenocarcinoma), not yet described.
Conclusions: MITF gene expression levels were detected in the peripheral blood from both people suffering from melanoma
and people without any type of cancer. However, variability in the number of molecules in MITF gene expression was observed
in people with melanoma, this suggests the presence of tumour cells in circulation.
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Evaluación de la expresión del factor de transcripción asociado con microftalmia (MITF) en sangre periférica de
individuos con y sin melanoma maligno y en líneas celulares
RESUMEN
Introducción: La incidencia de melanoma maligno se ha incrementado más rápido que cualquier otro tipo de cáncer,
intensificando así la búsqueda de herramientas que faciliten la identificación temprana del melanoma. El factor de transcripción
asociado con microftalmia (MITF) es conocido como el regulador maestro de melanocitos. En el presente estudio se analiza
la expresión del gen MITF en sangre periférica de un grupo de individuos con melanoma, comparándola con un grupo de
personas sin cáncer y en algunas líneas celulares.
Materiales y métodos: Se extrajo ARN de 31 muestras de sangre periférica: 19 de pacientes con melanoma y 12 de personas
sin ningún tipo de cáncer. Se cuantificaron niveles de expresión tanto para el gen MITF como para los genes de expresión
constitutiva (β2M y GAPDH) mediante PCR tiempo real. Asimismo se evaluó la expresión de los mismos genes en cinco líneas
celulares.
Resultados: En todos los individuos se observó expresión del gen MITF, aunque no hubo diferencias estadísticamente
significativas entre los niveles de expresión en los grupos de estudio (p=0.09). Sin embargo, la expresión de MITF en el grupo
de pacientes con melanoma fue más variable que la observada en el grupo de personas sin cáncer. Asimismo, en la línea celular
de adenocarcinoma gástrico se detectó expresión del gen MITF, no descrita hasta el momento.
Conclusiones: Se encontraron niveles de expresión del gen MITF en sangre periférica tanto de personas con melanoma
como en personas sin cáncer. Sin embargo, la variabilidad en los niveles de expresión del gen MITF observados en personas
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con melanoma, sugiere la posible presencia de células
tumorales en circulación.
Palabras clave: Melanoma; MITF; qPCR; Células
tumorales en circulación; Cáncer.
The malign melanoma is considered in some countries
(United States and Australia) as a problem of public
health, and it is also classified as epidemic, because in
the last years its incidence has increased1. It is considered
among the most aggressive types of cancer and, in
Colombia, causes approximately 40% of deaths for skin
cancer2, reason why it becomes important to implement
tests of early detection, prediction and pursuit based on
molecular markers, besides, to guide and facilitate the
development of new treatment options. At the moment
the attention is focused in the detection of tumoral cells
in circulation in peripheral blood, as promissory tool for
the identification of either people with early stage of the
illness and/or with clinical results potentially poor.
Smith et al.3 were the first ones in suggesting that
melanoma cells could be detected in peripheral blood
when identifying specific molecules of RNAm of tumoral
cells in circulation (tyrosine kinase RNAm), but absent
in non malign normal cells. Based on this original report,
several groups of researches have used this and other
methodologies to detect the expression of specific genes
from melanocytes in circulation (tirosyne kinase, Dct,
Mart-1)4,5. Nevertheless, in other studies is argued that
these genes are not sufficiently good candidates for the
analysis, mainly in advanced stages of the illness, because
their molecules of RNAm are not detected in a constant
way in peripheral blood in individuals with melanoma6.
Regarding to microphthalmia associated transcription
factor (MITF), it has been demonstrated that it plays a
crucial role in the cell differentiation and proliferation, as
well as in the post-natal (after life) viability of melanocytes
because it regulates the expression of genes like p21,
INK4a, CDK2, BCL2, TYR, DCT, among others, when
it is activated mainly through the pathways MAPK,
cAMP / PKA / CREB and Wnt-catenin7,8. There has
been described nine different promoters in the gene
MITF , each one codifies a unique isoform with end 5',
although they have in common the exons 2 to 9 which
codify for the functional domain of the transcription
factors. There is some information about the presence
of some of the isoforms in the way of specific-tissue as
it is the case of the isoform MC, expressed specifically
in mast cells and the M isoform expressed in melano-
cytes9. Also, immunohistochemistry techniques in
tumoral tissue have shown that the MITF gene expre-
ssion, incontrasr to other specific markers of pigmented
cells, remains in many, but in all the tumors of melanocytic
origin, establishing it as a sufficiently sensitive marker to
be kept in mind as possible tool to complement those
which are used in the present time for the diagnosis of
the melanoma and relieving their importance in the
development of the illness10,11. For that reason, in the
present analytic study of cases and controls, the MITF
gene expression was evaluated in peripheral blood from
individuals with malign melanoma (stage III and IV),
and it was compared with the expression in peripheral
blood from healthy people by means of real-time PCR
(qPCR) and in different cell lines.
MATERIALS AND METHODS
Cell culture. Five cell lines were used to evaluate
the MITF gene expression. The cell line A-375 (malign
melanoma) was used as a positive control; it was
obtained directly from ATCC (American Type Culture
Collection) while cell lines AGS and MCF-7 (gastric
adenocarcinoma and breast cancer, respectively) were
donated for the Instituto Nacional de Cancerología
(INC,), Bogotá, Colombia. The cell lines were kept in
cultivation according to the supplier specifications. In
general, the means of cultivation DMEM was supplied
with 10% fetal bovine serum (SFB) and they were
incubated at 37ºC with 5% CO2. From skin biopsies
primary cultures of melanocytes (CPM) and fibroblasts
(CPF) were generated, which were undergone the
action of 5% Dispase II solution (Molecular Roche
Biochemicals).
The disintegrated fragments of epidermis (melano-
cytes) were placed in a Petri sterile box with 2 ml of
specific growth medium of melanocytes (Cell Applica-
tion) and the dermis fragments (fibroblasts) were placed
in a Petri sterile box with 2 ml of DMEM enriched with
10% SFB. The obtained cells were incubated at 37ºC
and 5% CO2, until they reached a70% confluence; once
it happened, they were treated with trypsin EDTA
(0.25% for 60 seg) to remove the cells and using
TRIZOL to prepare the cell extracts to isolate total
RNA.
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Selection of cases and  controls. Keeping in mind
the incidence of the illness in the population of the
present study and previous reports5, representative
sample size was calculated to be count on the study
using the program sample size 1.1: 19 patients with
malign melanoma diagnosed both clinically and histolo-
gically according to the AJCC (American Joint
Committee on Cancer), 12 with metastasis to lymphatic
regional nodules (stage III) and 7 with distant metastasis
(stage IV); there were recruited to participate in this
study (13 men, 6 women among 13 and 86 years of age).
All patients were diagnosed, treated and supervised in
the Units of Dermatology and Breast and Soft Tissue of
the Instituto Nacional de Cancerología (INC), Bogotá,
Colombia. There were excluded of the study the patients
that had received systemic anti-neoplastic therapy
(chemo or radiotherapy). The control group included 12
people (eight men and four women) without any sort of
cancer who shared similar characteristics of gender,
age, occupation and socioeconomic condition, in order to
carry out a paired analysis and to control possible
variables of confusion exposition to ultraviolet radiation.
All participant individuals signed informed consent which
were approved by the committees of ethics of the
Universidad del Rosario and INC, according to the
declaration of Helsinki.
Gathering and processing indictment of blood
samples. They were gathered in vacutainer tubes with
EDTA samples of blood (5 ml) from patients with
melanoma and healthy people and processed maximum
from 2 to 3 hours after the gathering. Leucocytes and
other mononuclear cells were separated using a gradient
of Ficoll Histopaque-1077 (Sima Aldrich) and centrifuged
to 2000 rpm for 20 min. Total RNA was isolated from
mononuclear cells using TRIZOL (InvitrogenTM, Life
Technologies), technique on guanidinium thiocyanate-
phenol-chloroform extraction method concentration,
purity and integrity of the total RNA was determined by
spectrofotometry and visualized by denaturing agarose
gel electrophoresis at 1% for the later synthesis of the
DNAc.
RT-PCRand cDNA synthesis. Total RNA was
undergone to enzymatic digestion with DNAse I
amplification grade (InvitrogenTM, Life Technologies),
to eliminate traces of genomic DNA. For each sample
included in the study, two reactions of RT-PCR (Reverse
Transcription Polymerase Chain Reaction) were carried
out with the Kit SuperScript First-Strand Synthesis
System (InvitrogenTM, Life Technologies). cDNA was
synthesized accordinato supplier’s instructions. 1 μg of
total RNA was mixed shortly with 0.4 mM of dNTPs, 20
ng oligo (dT) and DEPC water. The solution was under-
gone to a process of denaturation, heating at 65ºC for 5
min. Then it was completed to a final volume of 25μl
adding buffer RT 1X, 4 mM MgCl2, 8 MM DTT, 40
RnaseOUTTM and 50μ SuperScriptTM II. The reaction
mixture was incubated at 42ºC for 50 min and the
polymerase activity was blocked at 70ºC for 15 min. 2u
of RNase H were added to the mixture, which was
incubated at 37ºC by 20 min to eliminate traces of RNA.
Real-time PCR (qPCR). By means of real-time
PCR, with specific primers of each gene some DNA
regions were amplified to evaluate the GAPDH, β2M
and MITF genes expression, using SYBR Green ITM
fluorescent dye that binds to double stranded DNA in
the detector of fluorescence Opticon II (MJ Research).
4 μl of cDNA were turned into a final volume of 20 μl,
using the mixture of reaction of Kit Platinum® SYBR®
Green qPCR SuperMix UDG 2X (InvitrogenTM, Life
Technologies). The final concentration of the components
in the mixture for real-time PCR amplication was:
Master Mix 1X, (1.5U Platinum® Taq DNA Polimerase,
20 mM Tris-HCl (pH 8.4), 50 mM KCl, 3 mM MgCl2,
200 μM c/u dNTPs, 1U UDG) and 0.5 μM for each
primer (Table 1)12 in distilled sterile H2O. The PCR
conditions used were the same ones for the three genes:
50°C for 3 min, 94°C for 15 min, 40 cycles at 95°C for
15 seg, 58°C for 30 seg, Plate Read (Reading of
Fluorescence) and 72°C for 30 seg, then 72°C for 5 min
and lastly the dissociation curve was obtained among
70ºC and 90°C. The amplified products of the genes
â2M and GAPDH, were purified with Kit QIAquick®
PCR Purification (Quiagen), quantified by spectro-
fotometry (TECAN® Genios) and used directly to carry
out dilutions and to generate standard curves in the real-
time PCR equipment. The PCR product of MITF gene
was purified and cloned in the plasmid vector TOPO 2.1
(InvitrogenTM, Life Technologies) in order to generate
a more stable and specific product to be used in standard
curves.
Statistical analysis. The expression levels among
the groups were compared using analysis of relative
quantification with the method published for Pfaffl, M13.
Also, analyses of absolute quantification, to determine
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Table 1
Oligo sequences used as primers
  Gene       Primera                        Sequence                             S/AS           Product size
GAPDH GAPD-5’ GAAATCCCATCACCATCTTCCAGG S 121 Pb
GAPD-3’ TGAGCCCCAGCCTTCTCCAT AS
β2M B2M-5’ AATTCACCCCCACTGAAAAA S 124 Pb
B2M-3’ GCGGCATCTTCAAACCTC AS
MITF MITF-5’ GCGCAAAAGAACTTGAAAAC S 124 Pb
Consensus MITF-3’ CGTGGATGGAATAAGGGAAA AS
a. The primers were designed using the program Oligo 5, according to the recommendations reported by Bustin SA12
the number of molecules, made possible to the research
team established a normal distribution of the data,
applying the test Shapiro-Wilks. Significant differences
among the studied groups for the levels of expression of
number of molecules of MITF, GAPDH and β2M
genes, were evaluated using the non parametric tests
Kruskal-Wallis and the test of ranges with sign of
Wilcoxon. For every test the significance level was 95%
(p=0 .05) in the statistical program SPSS (Version 12).
RESULTS
The cases group was constituded for 19 malign
melanoma patients, whose main characteristic was the
clinical stage of the tumor (III and IV). In the real-time
PCR tests carried out for GAPDH and β2M genes, it
was detected amplification of those genes in all the
studied patients. However, seven cases were excluded
because in the exploratory analysis with a box and
whisker plot (not shown data), atypical value and ends
atypical were observed, indicating that integrity and
quality of the blood sample was low and it could also
generate erroneous results in the final analysis. As a 1:1
equivalence was made by sex, age, stratum and
occupation, the statistical paired analyses were carried
out with 12 patients with malign melanoma and 12
people without any cancer type. The quantity of RNA
obtained from this group of cases varied between 10 and
15 μg for sample, using for test 1 μg. Also, the absorbance
at 280 nm was calculated and its relationship with the
absorbance 260 nm (260/280) provided data superior to
1.7, indicating the good quality and purity of the extracted
material.
Standard curves and analysis of efficiency.
Quantification methods (absolute and relative) require
equality or at least similarity in the PCR efficiencies of
every gene with a low level of variation (preferrably
between 90% and 100% of efficiency), on purpose to
obtain real and reliable data for analysis of
quantification14. The purified and quantified fragments
of the GAPDH and β2M genes, as well as of the MITF
fragment gene, were cloned in the TOPO plasmid and
for the standard curves. The detection limit for all the
curves it was between 1x109 and 100 molecules that
correspond to the minor and bigger C(t) (Cycle threshold)
detected, respectively (Graphic 1a). The efficiency in
the amplification of the three studied genes were between
95% and 100% and it was analyzed using the formula E
= [10 (-1 /-S)] where S is the value of the slope of the curve.
Also, the melting curve analysis in the range of
temperature between 70ºC and 90°C allowed to deter-
mine the primers specificity, because it was only observed
a peak or melting point for each gene (Graphic 1b).
Quantification of the MITF gene in cell lines. In
the cell lines (A-375, AGS, MCF-7) and in the
melanocytes primary cultures (CPM,) and fibroblasts
primary cultures (CPF), product of amplification was
obtained when specific primers of GADH and β2M
genes were used. At least two independent experiments
were made for each cell line in culture, obtaining very
similar data, which assured the reproducibility of the
real-time PCR tests. The data among culture and genes,
showed important similarity in their C(t)s, which allowed
the research team to establish initially GAPDH and
β2M as genes that are expressed in a relatively constant
way in the cell cultures analyzed (data not show).
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In the malign melanoma A-375 cell line and in the
primary culture of melanocytes (CPM), it was possible
to detect the MITF gene expression. MITF gene
expression was also evidenced in the of gastric cancer
(AGS) cell line, which was an unexpected fact, because
these cells are from gastric epithelial origin; in those
cells it was not expected to find MIFT gene expression
and there is any report type concerning to the evaluated
gene expression. The gen expression levels in the
primary culture of fibroblast (CPF) and in the breast
cancer (MCF-7) cell line were very low, being located
outside the detection limit. For that reason they were
considered negatives for the MITF gene expression
(Graphic 2).
 MITF gene quantification in the cases and
controls groups. When analyses of absolute
quantification were made, the calculated mean for the
expression levels of GAPDH gene was between 10 and
12 million of molecules; it applies for the cases group as
well as for the controls group. On the other hand, the
mean in β2M gene expression were between 41 and 43
millions of molecules for patients with malign melanoma
and people without cancer (Graphic 3). As controls
were selected keeping in mind similar characteristics of
Graphic 1. Standard curve of GAPDH gene. a. Curve generated by the software Opticon Monitor 2.0 (MJ
Research). There were made eight serial dilutions establishing an identical detection limit for the three
analyzed genes: 1x109 molecules (max) and 100 molecules (min). The slope data for GAPDH, β2M and MITF
were -0.30, -0.31 and -0.29 respectively (no curves shown for MITF and β2M). b. Dissociation Curve (curve
of Melting), specific for the MITF gene, made with each sample included in the standard curve.
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gender, age, occupation and socioeconomic condition to
those of the patients, the analyses were made in a paired
way, applying the Wilcoxon signed-rank non parametric
test which didn’t show significant differences in the levels
of GAPDH expression (p=0.388) and β2M expression
(p=0.347) genes between the pairs of the study groups.
MITF gene expression was detected in every individual
with malign melanoma and everyone without any kind of
cancer through absolute quantification analysis. However
it was observed bigger variability in the levels of expression
in the cases group, fact that is confirmed when the dispersion
of their samples was compared with the dispersion of the
samples of the control group (Graphic 3). The expression
levels for each one of the evaluated groups, were between
2,700 and 3,300 molecules. When the statistical tests were
applied with raw data of C(t) (Wilcoxon p=0.38) there
were not significant differences (p>0.05) in the levels of
MITF gene expression between patient with melanoma
and people without any cancer type. In the same way, there
were not significant differences when comparing the number
of molecules of MITF gene, between cases and controls
groups (p>0.05). However, there are reflected small
differences in the fact that in 8 of the 12 analyzed couples,
the cases showed bigger levels expression (Table 2a,
Graphic 3). Relative quantification analysis carried out with
the method published by Pfaffl12, which keep in mind
the amplification efficiency of the white gene (MITF)
and the normalizer gene (GAPDH), allowed to
evidence that on average, the difference in the level
of MITF expression gene was 1.34 times higher in
the cases group than the control group (Table 2a, b),
This result confirm the small differences that were
found in the absolute quantification analysis.
DISCUSSION
The detection of tumoral cells in peripheral blood
of patient with cancer is a procedure that has been
broadly used to identify specific tumor RNAm
molecules in several types of malignancy, for example
in prostate cancer, breast cancer and malign
melanoma15. However, there are some difficulties to
detect and quantify the RNAm, particularly, because
of the great variability and lack of sensitivity of the
used techniques, being RT-PCR one of the techniques
with high level of sensitivity and specificity, reason
why it is frequently used for genetic expression
analysis. Also, the more used biomarker to detect
tumoral cells in blood from patient with melanoma,
the tirosyne kinase (key enzyme for the biosynthesis
of melanin), shows considerable variations in its
detection of which goes from 0%16 to 100%17. It
makes necessary the search of other markers with
lesser variability. Differing from the studies mentioned
in the present work, the quantitative PCR was used
(qPCR) to detect the MITF gene expression levels
in peripheral blood in patients with malign melanoma
as indicator of the presence of tumoral cells in
circulation.
The quantitative analysis of the MITF gene
expression was made applying the methods of absolute
and relative quantification, based on the generation
of standard curves. These were created from a
plasmid that contained a fragment the of 124pb
corresponding to the consensus sequence of the
gene (the melanocytes expresses other isoforms of
MITF-m). Cell cultures analyses revealed MITF
gene expression levels in the malign melanoma (A-
375) cell line and in the primary culture of melanocytes
(CPM). In the breast cancer (MCF) cell line -7 and
the primary culture of fibroblasts (CPF), signs of
belated amplification were detected, data which
Graphic 2. Level of expression of the MITF gene in cell
lines. The expression levels in MCF-7 and CPF were
very low, therefore these cellular cultivations were
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were practically not quantifiable and therefore considered negatives for the
MITF gene expression. The reproducibility of data, obtained from two
independent experiments by triplication of the cell lines (MCF-7 and CPF),
could be explained by illegitimate gene transcription, reported in some
investigations18, as the responsible one of generating very low expression
levels of any gene in any cellular type. In the gastric cancer (AGS) cell line,
an average of 90 molecules was detected after carrying out two independent
experiments by triplication. The MITF gene expression in the gastric tissue
has not been sufficiently informed. Therefore these data are may be the first
report of the gene expression in this cell line and possibly, the first one that
suggest the expression of one or more isoforms of the MITF gene in the
gastric tissue.
It was found MITF gene expression in the 12 patients with malign
melanoma (stages III-IV) as well as in 12 people without any cancer type.
The relative quantification analysis showed that on average, the cases
group expressed 1.34 times more the MITF gene than the group of people
without cancer; in the absolute
quantification analysis when compa-
ring the obtained data (number of
molecules) in a paired way (case-
control), no significant statistical
differences were found in the MITF
gene expression level, between the
evaluated groups (p>0.05). Erro-
neous estimates were discarded
during the quantification process
because there were not found
significant differences in the genes
of constituent expression GAPDH
and β2M (p>0.05), indicating that
the procedures were carried out
technically correctly. MITF is
essential for the development and
survivor of melanocytes and appa-
rently, it also performs this important
role in other cell types when codifies
for MITF isoforms that have
different N-term endings. One of
them is MITF-A expressed in mast
cells19, which are recognized as the
principal efectors in allergic and
inflammatory reactions, derived from
hematopoyetic stem cells. The
movement of these cells alono the
blood and lymph vessels, as well as
the identification of the MITF protein
by inmunohistochemical analyses in
lymphocytes20, could explain the
detection of the gene in people with
malign melanoma as well as in people
without any type of cancer and in the
same way, it could justify why no
significant differences between the
studied groups were found. Although
no significant differences were
observed in the absolute quanti-
fication, small differences (p=0.09)
were reflected by the wide variability
in the levels of MITF gene expression
(Graphic 3), as well as, the small
increase in expression level of the
observed cases when relative










Graphic 3. Absolute quantification analysis. The distribution of cases
and controls for the GAPDH and β2M genes show very similar levels
of expression, indicating the utility of those as constituent expression
genes, as well as the good data processing and quality of the
analyzed samples. The distribution of the cases reflects the variability
in the MITF gene expression compared with its expression the group
of controls. The mean in the expression of the group of cases was
3,269 molecules (Ct: 24,64) while in the group of people without
cancer was 2,730 (Ct: 24,91). The variability in the MITF gene expression
can be corroborated by the fact that, even the statistics tests didn’t
reveal significant differences (p>;0.05), their value are located very
near the limit (p=0.09), suggesting that in future studies, it is necessary
to enlarge the panel of markers and the sample size to be analyzed.
Levels of expression
 Control   Case     Control   Case     Control    Case
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(Figure 2b), suggesting that a higher genetic instability
could exist in the cases group of cases circulating cells,
which is confirmed by cytogenetic studies made by the
research team; it could be explained by the presence of
tumoral cells in peripheral blood of patient with melanoma.
The similarities in the MITF gene expression levels
between the studied groups, suggests that this gene is
broadly expressed, indicating that it can be a gene of
constituent expression that can little contribute in the
specific diagnosis of the melanoma, just as it is expressed
by some authors9,10. Nevertheless, it must keep in mind
that while the MITF gene expression in people without
cancer was relatively constant, in the group of people
with melanoma the observed expression was much
more variable. Therefore, it is possible that enlarging the
number of individuals to be analyzed and using a panel
of biomarkers that include, for example, tirosyne kinase
and the melanocytes specific isoform of the MIFT gene
(MITF-m), it could be obtained a higher specificity and
sensitivity to develop and validate molecular diagnosis
tests, that allow to detect circulating tumoral cells in
patient with melanoma.
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